IOVA241108P8000
- 0.15
- 0.000.00%
Iovance Biotherapeutics Newsroom
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32
Promising Efficacy and Long-term Response of Iovance Biotherapeutics' Lifileucel in NSCLC: A Buy Recommendation
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Daily options tracking | Included in the Dow Jones component stocks! Nvidia rose 2% most profitable with call options doubling in a single day; "Audit Scandal" unfinished, super micro computer put options skyrocketing for consecutive days.
Amazon's performance surged by 6% after the earnings report, with large investors betting on selling put options and being bullish. The largest single transaction involved $2.7 million; China's large cap stock ETF experienced a sharp increase in implied volatility levels, as the market awaits the expected outcome.
Iovance Biotherapeutics (NASDAQ:IOVA) Delivers Shareholders Solid 166% Return Over 1 Year, Surging 4.9% in the Last Week Alone
Earnings Preview: IOVA to Report Financial Results Post-market on November 07
$Iovance Biotherapeutics(IOVA.US)$ is scheduled to release its financial results post-market on November 07 ET. Earnings PreviewAnalysts estimate $Iovance Biotherapeutics(IOVA.US)$ to post revenue
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Why Iovance Biotherapeutics Stock Triumphed on Thursday
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
Iovance Biotherapeutics Analyst Ratings
UBS Initiates Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $17
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc
Piper Sandler Maintains Iovance Biotherapeutics(IOVA.US) With Hold Rating, Maintains Target Price $10
Stifel Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $23
Stifel Nicolaus Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy?
Bullish Iovance Biotherapeutics Insiders Loaded Up On US$48.3m Of Stock
Iovance Biotherapeutics (NASDAQ:IOVA) Delivers Shareholders Favorable 74% Return Over 1 Year, Surging 4.9% in the Last Week Alone
3 Things You Need to Know If You Buy Iovance Biotherapeutics Today